Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
- PMID: 32502457
- DOI: 10.1016/S1470-2045(20)30064-4
Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
Erratum in
-
Correction to Lancet Oncol 2020; 21: e305-16.Lancet Oncol. 2020 Dec;21(12):e553. doi: 10.1016/S1470-2045(20)30671-9. Lancet Oncol. 2020. PMID: 33271110 No abstract available.
Abstract
Paediatric low-grade gliomas (also known as pLGG) are the most common type of CNS tumours in children. In general, paediatric low-grade gliomas show clinical and biological features that are distinct from adult low-grade gliomas, and the developing paediatric brain is more susceptible to toxic late effects of the tumour and its treatment. Therefore, response assessment in children requires additional considerations compared with the adult Response Assessment in Neuro-Oncology criteria. There are no standardised response criteria in paediatric clinical trials, which makes it more difficult to compare responses across studies. The Response Assessment in Pediatric Neuro-Oncology working group, consisting of an international panel of paediatric and adult neuro-oncologists, clinicians, radiologists, radiation oncologists, and neurosurgeons, was established to address issues and unique challenges in assessing response in children with CNS tumours. We established a subcommittee to develop consensus recommendations for response assessment in paediatric low-grade gliomas. Final recommendations were based on literature review, current practice, and expert opinion of working group members. Consensus recommendations include imaging response assessments, with additional guidelines for visual functional outcomes in patients with optic pathway tumours. As with previous consensus recommendations, these recommendations will need to be validated in prospective clinical trials.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Similar articles
-
Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.Lancet Oncol. 2020 Jun;21(6):e317-e329. doi: 10.1016/S1470-2045(20)30173-X. Lancet Oncol. 2020. PMID: 32502458 Review.
-
Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.Lancet Oncol. 2020 Jun;21(6):e330-e336. doi: 10.1016/S1470-2045(20)30166-2. Lancet Oncol. 2020. PMID: 32502459 Review.
-
Response assessment in paediatric intracranial ependymoma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.Lancet Oncol. 2022 Aug;23(8):e393-e401. doi: 10.1016/S1470-2045(22)00222-4. Lancet Oncol. 2022. PMID: 35901835 Review.
-
Response Assessment in Neuro-Oncology Clinical Trials.J Clin Oncol. 2017 Jul 20;35(21):2439-2449. doi: 10.1200/JCO.2017.72.7511. Epub 2017 Jun 22. J Clin Oncol. 2017. PMID: 28640707 Free PMC article. Review.
-
Response assessment in pediatric neurooncology (RAPNO) criteria revisited: a practical navigation guide for neuroradiologists.Neuroradiology. 2024 Dec;66(12):2117-2142. doi: 10.1007/s00234-024-03493-x. Epub 2024 Oct 24. Neuroradiology. 2024. PMID: 39446196 Review.
Cited by
-
European Society for Paediatric Oncology (SIOPE) MRI guidelines for imaging patients with central nervous system tumours.Childs Nerv Syst. 2021 Aug;37(8):2497-2508. doi: 10.1007/s00381-021-05199-4. Epub 2021 May 10. Childs Nerv Syst. 2021. PMID: 33973057 Review.
-
Imaging of pediatric brain tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee/ASPNR White Paper.Pediatr Blood Cancer. 2023 Jun;70 Suppl 4(Suppl 4):e30147. doi: 10.1002/pbc.30147. Epub 2022 Dec 15. Pediatr Blood Cancer. 2023. PMID: 36519599 Free PMC article.
-
Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium.Clin Cancer Res. 2024 Jun 3;30(11):2303-2308. doi: 10.1158/1078-0432.CCR-23-3386. Clin Cancer Res. 2024. PMID: 38358393 Free PMC article.
-
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma.Clin Cancer Res. 2025 Apr 14;31(8):1383-1389. doi: 10.1158/1078-0432.CCR-24-3439. Clin Cancer Res. 2025. PMID: 39808502 Clinical Trial.
-
A critical review of RAF inhibitors in BRAF-mutated glioma treatment.Pharmacogenomics. 2024;25(7):343-355. doi: 10.1080/14622416.2024.2355859. Epub 2024 Jun 3. Pharmacogenomics. 2024. PMID: 38884947 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials